


=> d 11
L1 HAS NO ANSWERS
L1 STR



VAR G1=2/3
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> s 11 ful
FULL SEARCH INITIATED 17:26:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L3 9 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 158.87 159.08

FILE 'CAPLUS' ENTERED AT 17:26:12 ON 02 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Dec 2004 VOL 141 ISS 23

FILE LAST UPDATED: 1 Dec 2004 (20041201/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4 3 L3

=> d bib abs hitstr 1-3


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:886852 CAPLUS
DN 136:20008
TI Preparation of aromatic sulfonyl alpha-cycloamino hydroxamates as MMP inhibitors
IN Becker, Daniel P.; Li, Madeleine H.; DeCrescenzo, Gary A.
PA USA
SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 254,530, abandoned.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001049449	A1	20011206	US 2001-778411	20010207
	US 6638952	B1	20031028	US 1999-254530	19991223
	WO 2002062756	A1	20020815	WO 2002-US3448	20020207
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1358155	A1	20031105	EP 2002-720921	20020207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 1999-254530	B2	19991223		
	US 1997-35182P	P	19970304		
	WO 1998-US4273	W	19980304		
	US 2001-778411	A	20010207		
	WO 2002-US3448	W	20020207		
OS	MARPAT 136:20008				
GI					



I

AB Aromatic sulfonyl alpha-cycloamino hydroxamic acid compds. (I), and pharmaceutically acceptable salts thereof, that inhibit matrix metalloprotease activity, are disclosed. Thus, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-1-(2-propynyl)-2-pyrrolidine carboxamide monohydrochloride was prepared in several steps. Inhibition of MMP-1, MMP-2, and MMP-13 by I was determined

IT 377739-52-1P 377739-55-4P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic sulfonyl alpha-cycloamino hydroxamates as MMP inhibitors)

RN 377739-52-1 CAPLUS



CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-1-(2-propynyl)-, (2R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 377739-51-0

CMF C21 H22 N2 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 377739-55-4 CAPLUS



CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-phenoxyphenyl)sulfonyl]methyl]-1-(2-propynyl)-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 377739-54-3

CMF C21 H22 N2 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 213013-94-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aromatic sulfonyl alpha-cycloamino hydroxamates as MMP

inhibitors)

RN 213013-94-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-1-(2-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 377739-51-0P 377739-54-3P 377739-57-6P

377739-58-7P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aromatic sulfonyl alpha-cycloamino hydroxamates as MMP inhibitors)

RN 377739-51-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-1-(2-propynyl)-, (2R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 377739-54-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-1-(2-propynyl)-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 377739-57-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-1-(2-propynyl)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 377739-58-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-1-(2-propynyl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 377739-54-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-1-(2-propynyl)-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 397330-29-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-1-(2-propynyl)- (9CI) (CA INDEX NAME)





L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:746581 CAPLUS
 DN 136:167154
 TI α -Alkyl- α -amino- β -sulfone hydroxamates as potent MMP
 inhibitors that spare MMP-1
 AU Becker, D. P.; DeCrescenzo, G.; Freskos, J.; Getman, D. P.; Hockerman, S.
 L.; Li, M.; Mehta, P.; Munie, G. E.; Swearingen, C.
 CS Departments of Medicinal Chemistry and Inflammation-Oncology, Pharmacia
 Research & Development, Skokie, IL, 60077, USA
 SO Bioorganic & Medicinal Chemistry Letters (2001), 11(20), 2723-2725
 CODEN: BMCL8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB A series of α -alkyl- α -amino- β -sulfonyl hydroxamates
 HONHCOCR1(NR2R3)CH2SO2C6H4XPh-4 [R1 = Me, R2 = H, Ac, Me, Et, CH2Ph,
 CH2CH2Ph, 3,4-methylenedioxybenzyl, 2-naphthylmethyl, propargyl,
 pyrrolidinoacetyl, R3 = H, X = O; R1-R3 = Me, X = O; R1 = Me, R2 = H, Ac,
 R3 = H, X = S; R1 = Ph, R2 = Bz, H, R3 = H, X = O; R1R2 = (CH2)3, R3 =
 propargyl, X = O] was prepared and evaluated for potency vs. MMP-2 and
 MMP-13, and for selectivity vs. MMP-1. Low nanomolar potency was obtained
 with selectivity vs. MMP-1 ranging from >10 to >1000. Selected compds.
 were orally bioavailable.
 IT 377739-51-0P 377739-54-3P 397330-29-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (math>\alpha-alkyl- α -amino- β -sulfonyl hydroxamates as potent MMP
 inhibitors that spare MMP-1)
 RN 377739-51-0 CAPLUS
 CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-
 1-(2-propynyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:612088 CAPLUS
DN 129:260857
TI Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
IN Becker, Daniel P.; Villamil, Clara I.; Li, Madeleine H.; Boehm, Terri L.;
Getman, Daniel P.; McDonald, Joseph J.; Decrescenzo, Gary A.
PA Monsanto Company, USA
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9839315	A1	19980911	WO 1998-US4273	19980304
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2283272	AA	19980911	CA 1998-2283272	19980304
	AU 9866855	A1	19980922	AU 1998-66855	19980304
	EP 983257	A1	20000308	EP 1998-908949	19980304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI JP 2002515901	T2	20020528	JP 1998-538780	19980304
	US 6638952	B1	20031028	US 1999-254530	19991223
	US 2004097487	A1	20040520	US 2003-695278	20031027
PRAI	US 1997-35182P	P	19970304		
	WO 1998-US4273	W	19980304		
	US 1999-254530	A1	19991223		
OS	MARPAT 129:260857				
GI					




AB Aromatic sulfonyl alpha-cycloamino hydroxamic acid compds. I [m = 0-3; n = 0-2; m+n = 1-3; R2 = H, hydrocarbyl, arylhydrocarbyl, etc.; R1 = cyclohydrocarbyl, aryl, etc.] that inhibit matrix metalloprotease activity are disclosed. E.g., N-hydroxy-4-[[[4-(benzoylamino)phenyl]sulfonyl]methyl]-4-piperidinecarboxamide monohydrochloride was prepared in several steps. Inhibition of MMP-13, MMP-1, MMP-2, MMP-3, MMP-8, and MMP-9 by I was determined

IT 213013-94-6P 213013-95-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonyl hydroxamic acids as matrix metalloprotease inhibitors)

RN 213013-94-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]methyl-


1-(2-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 213013-95-7 CAPLUS


CN 2-Pyrrolidinecarboxamide, 2-[[[4-(3,4-dimethylphenoxy)phenyl]sulfonyl]methy l]-N-hydroxy-1-(2-propynyl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=> d 18
L8 HAS NO ANSWERS
L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

=> s 18 ful
FULL SEARCH INITIATED 17:29:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 387 TO ITERATE

100.0% PROCESSED 387 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L10 9 SEA SSS FUL L8

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	310.84	484.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-2.10

FILE 'CAPLUS' ENTERED AT 17:29:20 ON 02 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 2 Dec 2004 VOL 141 ISS 23
FILE LAST UPDATED: 1 Dec 2004 (20041201/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l10
L11 8 L10

=> s l10 not l3
8 L10
3 L3
L12 8 L10 NOT L3

=> d bib abs hitstr 1-8

L12 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:182866 CAPLUS
DN 140:236096
TI Preparation of proline derivatives as antibacterial agents
IN Fujita, Masahiro; Sakamoto, Masato; Horiuchi, Nobuhiko; Yamamoto, Takayoshi; Tomita, Kyoji; Mizuno, Kazuhiro; Niga, Toshiyuki; Ito, Hideaki; Kashimoto, Shigeki



PA Dainippon Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018453	A1	20040304	WO 2003-JP10548	20030821
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2002-242795	A	20020823		
	JP 2002-339200	A	20021122		
	JP 2003-27010	A	20030204		
OS	MARPAT	140:236096			
GI					



AB Proline derivs. represented by the general formula (I) or salts thereof [wherein A = a group derived from a 5- or 6-membered heterocycle which may be fused with an optionally halogenated benzene ring; p1, p2, p3 = 0, 1; R1, R2, R3 = H, lower alkoxy, lower alkylthio, halo, HO, (un)protected or (un)substituted NH2 or CONH2, hydroxy-lower alkylamino, CO2H, lower alkoxy carbonyl, lower alkylcarbonyloxy, (un)substituted lower alkylsulfonyloxy, cyano; when p1 = p2 = 1, CR1R2 = CO; or when p1 = p2 = p3 = 1, R1 = R2 = H and R3 = a 5- or 6-membered saturated or unsatd. cyclic group; T = a single bond, CH2, CO; R4, R5 = H, lower alkyl; or CR4R5 = CO; n, m = 1, 2; R6, R7 = H, OH, halogeno, lower alkyl, Ph, lower alkoxy, phenyl-lower alkyl, (un)protected NH2; R6 and R7 together form a saturated cyclic group; X = CH2, CH, S, O; Y = H, an amino-protecting group, or a group represented by the general formula R9ON(CHO)CH2CH(R8)CO; wherein R8 = alkyl, cycloalkyl-lower alkyl; R9 = H, a hydroxyl-protecting group, etc.] are prepared. These compds. are useful as antibacterial drugs against multidrug-resistant bacteria. Thus, (2R)-3-cyclopentyl-2-[N-(2,4-dimethoxybenzyloxy)-N-formylamino]methyl]propionic acid was condensed with (2S)-2-[(4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]pyrrolidine hydrochloride using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, and Et3N in CH2Cl2 at room temperature for 18 h to give 68% (2S)-1-[(2R)-3-cyclopentyl-2-[N-(2,4-dimethoxybenzyloxy)-N-formylamino]methyl]propionyl]-2-[(4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]pyrrolidine which was treated with 3% CF3CO2H in CH2Cl2 at room temperature for 17 h and then with saturated aqueous NaHCO3 under

ice-cooling to give 77% (2S)-1-[(2R)-3-cyclopentyl-2-[N-formyl-N-hydroxyamino]methyl]propionyl]-2-[(4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]pyrrolidine (II). II showed min. inhibitory concentration of 0.25, 0.125, 0.03, 0.25, 0.5, 0.125, 1, 0.5, and 0.125 µg/mL against *Staphylococcus aureus* Smith, *S. aureus* KTO150 (MRSA), *S. epidermidis* ATCC12228, *Streptococcus pneumoniae* ATCC49619, *S. pneumoniae* KT2524 (PRSP), *S. pneumoniae* KB2534 (PRSP), *S. pyogenes* ATCC12344, *Enterococcus faecium* ATCC19434, and *Moraxella (B.) catarrhalis* K1209, resp.

IT 668482-89-1P 668483-03-2P 668483-47-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of proline derivs. as antibacterial agents against

multidrug-resistant bacteria)

RN 668482-89-1 CAPLUS

CN Piperazine, 1-(3-cyano-2-pyridinyl)-4-[(2R)-N-formyl-N-hydroxy-2-pentyl-
β-alanyl-L-prolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668483-03-2 CAPLUS

CN Piperazine, 1-(3-cyanopyrazinyl)-4-[(2R)-N-formyl-N-hydroxy-2-pentyl-
β-alanyl-L-prolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668483-47-4 CAPLUS

CN Piperazine, 1-(4-cyano-2-thiazolyl)-4-[(2R)-N-formyl-N-hydroxy-2-pentyl-
β-alanyl-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:514259 CAPLUS
DN 137:78765
TI Preparation of phenylbicyclooctanecarboxylic acids
IN Nakai, Jirou; Kishikawa, Katsuya
PA Ono Pharmaceutical Co., Japan
SO Jpn. Kokai Tokkyo Koho, 48 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION

PI JP 2002193880 A2 20020710 JP 2000-399
PRAI JP 2000-399195 20001227
OS MARPAT 137:78765
GI

$$\begin{array}{c}
 \text{COR1} \\
 | \\
 \text{COR2} \\
 | \\
 \text{COR3} \\
 | \\
 \text{COR4}
 \end{array}
 \text{I}$$

AB The compds. I (R1 = OH, C1-8 alkoxy, NR5OR6, NR7R8, etc.; R5, R6 = H, C1-8 alkyl; R7, R8 = H, C1-8 alkyl, hetero ring; R2 = H, cyano; R3, R4 = C1-8 alkyl, C3-7 cycloalkyl, aromatic ring, hetero ring, etc.; dotted line represents optional double bond) or their nontoxic salts are prepared. The compds. are useful as antiinflammatory agents, antidiabetic agents, allergy inhibitors, autoimmune disease inhibitors, osteoporosis agents, antiobesity agents, antidepressants, antiparkinsonian agents, ischemia reperfusion injury inhibitors, leukemia inhibitors, etc.

(1R, 5R, 7R)-3-cyano-7-(3-cyclopentyloxy-4-methoxyphenyl)bicyclo[3.3.0]octa-2-ene and (1S, 5S, 7S)-3-cyano-7-(3-cyclopentyloxy-4-methoxyphenyl)bicyclo[3.3.0]octa-2-ene were treated with NaOH in ethylene glycol at 200° for 4 h to give 0.63 g mixture of (1R, 5R, 7R)-7-(3-cyclopentyloxy-4-methoxyphenyl)bicyclo[3.3.0]octa-2-en-3-ylcarboxylic acid and (1S, 5S, 7S)-7-(3-cyclopentyloxy-4-methoxyphenyl)bicyclo[3.3.0]octa-2-en-3-ylcarboxylic acid. The compound showed good phosphodiesterase inhibitory activity.

IT 439920-18-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylbicyclooctanecarboxylic acids)

RN 439920-18-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[5-[(2 α , 3 α β , 5 α , 6 α β]-2-cyanoctahydro-5-[(hydroxyamino)carbonyl]-2-pentenyl]-2-methoxyphenoxy]-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L12 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:444499 CAPLUS

DN 137:33207

TI Preparation of novel N-substituted- γ , γ -trisubstituted lactam derivatives as matrix metalloproteinase inhibitors

IN Duan, Jingwu; DeCicco, Carl P.; Wasserman, Zelda R.; Maduskuie, Thomas P., Jr.

PA USA

SO U.S., 119 pp.



CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6403632	B1	20020611	US 2000-516709	20000301
	US 2003134827	A1	20030717	US 2002-96619	20020312
	US 6610731	B2	20030826		
PRAI	US 1997-62418P	P	19971003		
	US 1998-165747	A3	19981002		
	US 2000-516709	A3	20000301		
OS	MARPAT 137:33207				
GI					



AB Title compds. [I; A is selected from COOH, CH₂COOH, CONHOH, SH, CH₂SH, PO(OH)₂, etc.; ring B is a 4-8 membered cyclic amide containing 0-3 heteroatoms from O, N, and S, etc.; R1 is phenylmethoxyphenyl, phenoxyphenyl, etc.; R2 is H, CH₃, Et, i-Pr, etc.; R1-R2 combine to form heterocyclic; R3 is H, alkylene, heterocyclic, etc.; R4 is H, alkylene, etc.; R3-R4 combine to form heterocyclic], stereoisomer, and pharmaceutically acceptable salt thereof are prepared as useful metalloprotease inhibitors. For instance, 4-benzyloxyphenyl acetate was sequentially alkylated (THF, NaHMDS) with MeI and allyl bromide to afford the α,α -bis(alkylated) derivative which was converted to the aldehyde (CH₂Cl₂, O₃) and was subsequently reacted with D-alanine Me ester hydrochloride and Zn⁺ in HOAc to yield the lactam ester. This intermediate was treated with hydroxylamine to give hydroxamic acid II.


IT **223401-56-7P**, 1-Pyrrolidineacetamide, 3-[4-[(3-cyanophenyl)methoxy]phenyl]-N-hydroxy- α ,3-dimethyl-2-oxo-, (α R)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(N- γ , γ -trisubstituted lactam derivs. as MMP-3/aggreccanase inhibitors)

RN 223401-56-7 CAPLUS

CN 1-Pyrrolidineacetamide, 3-[4-[(3-cyanophenyl)methoxy]phenyl]-N-hydroxy- α ,3-dimethyl-2-oxo-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:703781 CAPLUS
 DN 135:257040
 TI Preparation of hydroxamates as matrix metalloproteinase inhibitors
 IN Curtin, Michael L.; Dai, Yujia; Davidsen, Steven K.; Dellaria, Joseph F., Jr.; Florjancic, Alan S.; Gong, Jianchun; Guo, Yan; Heyman, Howard R.; Holms, James H.; Michaelides, Michael R.; Stacey, Jamie R.; Steinman, Douglas H.; Wada, Carol K.; Xu, Lianhong
 PA Abbott Laboratories, USA
 SO U.S., 87 pp., Cont.-in-part of U.S. Ser. No. 239,087.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6294573	B1	20010925	US 2000-492567	20000127
	US 2002007060	A1	20020117	US 2001-905242	20010716
PRAI	US 1997-55103P	P	19970806		
	US 1998-129360	B2	19980805		
	US 1999-239087	A2	19990127		
OS	MARPAT 135:257040				
GI					



II


AB RZZ1Z2CR3R4CR1R2N(OH)CHO [I; R = (un)substituted (hetero)aryl; R1,R3 = H or alkyl; R2,R4 = H (un)substituted alkyl, phenyl(alkyl), etc.; Z = bond, O, CO, alkylene, etc.; Z1 = (un)substituted phenylene; Z2 = O, CO, SO2NH, etc.] were prepared. Thus, epibromohydrin was etherified by PhOH and the product etherified by 4-(HO)C6H4C6H4(CN)-4 to give PhOCH2CH(OH)CH2OC6H4[C6H4(CN)-4]-4 which was aminated by HN(CO2CMe3)OCO2CMe3 to give, after deprotection and formylation, title compound II. Data for biol. activity of I were given.

IT 220614-84-6P 220614-89-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamates as matrix metalloproteinase inhibitors)



RN 220614-84-6 CAPLUS

CN Formamide, N-[2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 220614-89-1 CAPLUS

CN Formamide, N-[2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(3-ethyl-3-methyl-2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:456652 CAPLUS
 DN 135:226761
 TI Biaryl Ether Retrohydroxamates as Potent, Long-lived, Orally Bioavailable MMP Inhibitors
 AU Michaelides, M. R.; Dellaria, J. F.; Gong, J.; Holms, J. H.; Bouska, J. J.; Stacey, J.; Wada, C.; Heyman, H. R.; Curtin, M. L.; Guo, Y.; Goodfellow, C. L.; Elmore, I. B.; Albert, D. H.; Magoc, T. J.; Marcotte, P. A.; Morgan, D. W.; Davidsen, S. K.
 CS Cancer Research Area, Dept. 47J, Abbott Laboratories, Abbott Park, IL, 60064, USA
 SO Bioorganic & Medicinal Chemistry Letters (2001), 11(12), 1553-1556
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 GI



AB A series of biaryl ether-containing hydroxamate matrix metalloproteinase (MMP) inhibitors such as I (R = H, Me, Et) has been developed. These compds. are potent MMP-2 inhibitors with limited activity against MMP-1. I (R = H) exhibited excellent pharmacokinetic properties with long elimination half-life (7 h) and high oral bioavailability (100%) in cynomolgous monkeys and marmosets.


IT **220614-84-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, potency, and bioavailability of biaryl ether hydroxamate derivs. as matrix metalloproteinase inhibitors)

RN 220614-84-6 CAPLUS

CN Formamide, N-[2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RE.CNT 9


THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:371704 CAPLUS
 DN 134:366875
 TI Preparation of N-(hetero)aralkyl-N-hydroxyformamides as matrix metalloproteinase inhibitors.
 IN Dai, Yujia; Davidsen, Steven K.; Michaelides, Michael R.; Stacey, Jamie R.; Steinman, Douglas H.; Wada, Carol K.
 PA Abbott Laboratories, USA
 SO U.S., 51 pp., Cont.-in-part of U.S. Ser. No. 238,377, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6235786	B1	20010522	US 2000-492718	20000127
PRAI US 1997-55103P	P	19970806		
US 1998-129360	B2	19980805		
US 1999-238377	B2	19990127		
OS MARPAT 134:366875				
GI				




AB N-Hydroxy formamide derivs. HCON(OH)CR1R2-CR3R4-X-C6H4-Y-Ar2 [R1 = H; R2 = H, or (alkylene)NR6R7 where R6, R7 taken together with the nitrogen is (thio)morpholinyl, pyrrolidinyl, etc.; R3, R4 = H or alkyl or R4 = H and R2, R3 taken together with the carbon atoms to which they are attached, form a 6-membered carbocyclic ring; X = (CH2)SO2, NHSO2 or alkyl derivs.; Y = a bond or O; Ar2 = (substituted by halo or perfluoroalkoxy) phenyl] are prepared. Over 100 examples are provided. Invention compds. are matrix metalloproteinase inhibitors; IC50 for stromelysin was 4.3 - 270 nM (17 examples) and gelatinase A was 0.6 - 120 nM (6 examples). For instance, N-Hydroxy-N-(2,2-Dimethyl-3-((4-phenoxyphenyl)sulfonyl)propyl)formamide (I; multistep preparation given) inhibited gelatinase with IC50 = 4.3 nM.
 IT 220614-84-6P 220614-87-9P 220614-88-0P
220614-89-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (hetero)aralkylhydroxyformamides as matrix metalloproteinase inhibitors)
 RN 220614-84-6 CAPLUS
 CN Formamide, N-[2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 220614-87-9 CAPLUS

CN Formamide, N-[(1S)-2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220614-88-0 CAPLUS


CN Formamide, N-[(1R)-2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220614-89-1 CAPLUS
CN Formamide, N-[2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(3-ethyl-3-methyl-2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L12 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:244635 CAPLUS
DN 130:296611
TI Preparation of novel lactam as metalloprotease inhibitors
IN Duan, Jingwu; Decicco, Carl P.; Wasserman, Zelda R.; Maduskuie, Thomas P., Jr.
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 333 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 9918074	A1	19990415	WO 1998-US21037	19981002
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL,				

RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE

ZA 9808967	A	20000403	ZA 1998-8967	19981001
CA 2305679	AA	19990415	CA 1998-2305679	19981002
AU 9896866	A1	19990427	AU 1998-96866	19981002
AU 747239	B2	20020509		
US 6057336	A	20000502	US 1998-165747	19981002
EP 1027332	A1	20000816	EP 1998-950954	19981002
EP 1027332	B1	20040526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9815398	A	20001031	BR 1998-15398	19981002
EE 200000199	A	20010416	EE 2000-200000199	19981002
JP 2001519331	T2	20011023	JP 2000-514886	19981002
AT 267805	E	20040615	AT 1998-950954	19981002
TW 541304	B	20030711	TW 1998-87116499	19981021
NO 2000000783	A	20000529	NO 2000-783	20000217
PRAI	US 1997-62418P	P	19971003	
	WO 1998-US21037	W	19981002	
OS	MARPAT 130:296611			

GI




AB Title compds. [I; A is selected from COOH, CH₂COOH, CONHOH, SH, CH₂SH, PO(OH)₂, etc.; ring B is a 4-8 membered cyclic amide containing 0-3 heteroatoms from O, N, and S, etc.; R1 is phenylmethoxyphenyl, phenoxyphenyl, etc.; R2 is H, CH₃, Et, i-Pr, etc.; R1-R2 combine to form heterocyclic; R3 is H, alkylene, heterocyclic, etc.; R4 is H, alkylene, etc.; R3-R4 combine to form heterocyclic], stereoisomer, and pharmaceutically acceptable salt thereof are prepared as useful metalloprotease inhibitors. Thus, compound II was prepared via alkylation, oxidation, amination, and cyclization.

IT 223401-56-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel lactam metalloprotease inhibitors)
 RN 223401-56-7 CAPLUS
 CN 1-Pyrrolidineacetamide, 3-[4-[(3-cyanophenyl)methoxy]phenyl]-N-hydroxy-
 α ,3-dimethyl-2-oxo-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:113642 CAPLUS
 DN 130:182466
 TI Preparation of N-(hetero)aralkyl-N-hydroxyformamides as matrix
 metalloproteinase inhibitors.
 IN Curtin, Michael L.; Davidsen, Steven K.; Dellaria, Joseph F., Jr.;
 Florjancic, Alan S.; Giesler, Jamie; Gong, Jianchun; Guo, Yan; Heyman, H.
 Robin; Holms, James H.; Michaelides, Michael R.; Steinman, Douglas H.;
 Wada, Carol K.; Xu, Lianhong
 PA Abbott Laboratories, USA
 SO PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906361	A2	19990211	WO 1998-US15486	19980727
	WO 9906361	A3	19990422		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9885139	A1	19990222	AU 1998-85139	19980727
	AU 758870	B2	20030403		
	EP 1001930	A2	20000524	EP 1998-936014	19980727
	EP 1001930	B1	20021204		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO			
	TR 9903287	T2	20000921	TR 1999-9903287	19980727


JP 2001523272	T2	20011120	JP 1999-511062	19980727
BR 9810760	A	20011127	BR 1998-10760	19980727
AT 228998	E	20021215	AT 1998-936014	19980727
PT 1001930	T	20030430	PT 1998-936014	19980727
ES 2189207	T3	20030701	ES 1998-936014	19980727
ZA 9806828	A	19990129	ZA 1998-6828	19980730
TW 466238	B	20011201	TW 1998-87112636	19981013
BG 64307	B1	20040930	BG 1999-103995	19991213
MX 9911694	A	20000531	MX 1999-11694	19991214
NO 9906579	A	20000124	NO 1999-6579	19991230
HK 1028023	A1	20031024	HK 2000-107516	20001123
PRAI US 1997-903632	A	19970731		
WO 1998-US15486	W	19980727		
OS MARPAT 130:182466				
AB ACON(OH)CR1R2CR3R4(CH ₂) _n XArlYAr2 [A = H; n = 0; R1, R3 = H, alkyl; R2, R4 = H, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy carbonylalkyl, haloalkyl, hydroxyalkyl, Ph, phenylalkoxyalkyl, phenylalkyl, phenoxyalkyl, heterocyclyloxyalkyl, etc.; R1R2C = spirocycloalkyl, tetrahydropyranyl; R3R4C = spirocycloalkyl; R1R3 = atoms to form a 5-7 membered carbocyclyl; X = O, NR ₅ SO ₂ , SO _p , CO; Ar1 = (substituted) Ph; Y = bond, O, alkylene, piperidinyl; alkenylene, alkynylene, SO _p , CO; Ar2 = (substituted) Ph, pyridyl, pyrazinyl, pyridazinyl, furyl, thienyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl; p undefined], were prepared. Thus, N-[1-[(4'-cyano-1,1'-biphenyl-4-yl)oxy]methyl]-2-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)ethyl-N-hydroxyformamide (multistep preparation given) inhibited stromelysin with IC ₅₀ = 9.1 nM.				
IT 220614-84-6P 220614-87-9P 220614-88-0P				
220614-89-1P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
				(preparation of (hetero)aralkylhydroxyformamides as matrix metalloproteinase inhibitors)
RN 220614-84-6 CAPLUS				
CN Formamide, N-[2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)				



RN 220614-87-9 CAPLUS

CN Formamide, N-[(1S)-2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220614-88-0 CAPLUS

CN Formamide, N-[(1R)-2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220614-89-1 CAPLUS

CN Formamide, N-[2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-1-[(3-ethyl-3-methyl-2,5-dioxo-1-pyrrolidinyl)methyl]ethyl]-N-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

